亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial

多西紫杉醇 凡德他尼 医学 内科学 肿瘤科 安慰剂 人口 肺癌 化疗 酪氨酸激酶 病理 环境卫生 受体 替代医学
作者
Roy S. Herbst,Yan Sun,Wilfried Eberhardt,Paul Germonpré,Nagahiro Saijo,Caicun Zhou,Jie Jin Wang,Longyun Li,Fairooz F. Kabbinavar,Yukito Ichinose,Shukui Qin,Li Zhang,Bonne Biesma,John V. Heymach,Peter Langmuir,Sarah M. Kennedy,H Tada,Bruce E. Johnson
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:11 (7): 619-626 被引量:388
标识
DOI:10.1016/s1470-2045(10)70132-7
摘要

Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR), and rearranged during transfection (RET) tyrosine kinases. In a randomised phase 2 study in patients with previously treated non-small-cell lung cancer (NSCLC), adding vandetanib 100 mg to docetaxel significantly improved progression-free survival (PFS) compared with docetaxel alone, including a longer PFS in women. These results supported investigation of the combination in this larger, definitive phase 3 trial (ZODIAC).Between May, 2006, and April, 2008, patients with locally advanced or metastatic (stage IIIB-IV) NSCLC after progression following first-line chemotherapy were randomly assigned 1:1 through a third-party interactive voice system to receive vandetanib (100 mg/day) plus docetaxel (75 mg/m(2) intravenously every 21 days; maximum six cycles) or placebo plus docetaxel. The primary objective was comparison of PFS between the two groups in the intention-to-treat population. Women were a coprimary analysis population. This study has been completed and is registered with ClinicalTrials.gov, number NCT00312377.1391 patients received vandetanib plus docetaxel (n=694 [197 women]) or placebo plus docetaxel (n=697 [224 women]). Vandetanib plus docetaxel led to a significant improvement in PFS versus placebo plus docetaxel (hazard ratio [HR] 0.79, 97.58% CI 0.70-0.90; p<0.0001); median PFS was 4.0 months in the vandetanib group versus 3.2 months in placebo group. A similar improvement in PFS with vandetanib plus docetaxel versus placebo plus docetaxel was seen in women (HR 0.79, 0.62-1.00, p=0.024); median PFS was 4.6 months in the vandetanib group versus 4.2 months in the placebo group. Among grade 3 or higher adverse events, rash (63/689 [9%] vs 7/690 [1%]), neutropenia (199/689 [29%] vs 164/690 [24%]), leukopenia (99/689 [14%] vs 77/690 [11%]), and febrile neutropenia (61/689 [9%] vs 48/690 [7%]) were more common with vandetanib plus docetaxel than with placebo plus docetaxel. The most common serious adverse event was febrile neutropenia (46/689 [7%] in the vandetanib group vs 38/690 [6%] in the placebo group).The addition of vandetanib to docetaxel provides a significant improvement in PFS in patients with advanced NSCLC after progression following first-line therapy.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
vfdhjng发布了新的文献求助10
刚刚
完美世界的应助被撩寮采纳,获得10
3秒前
康子浩发布了新的文献求助10
6秒前
多情嫣然完成签到,获得积分10
10秒前
11秒前
ZaZa完成签到,获得积分10
11秒前
14秒前
summerer发布了新的文献求助10
20秒前
Lucas的应助被科研通管家采纳,获得10
21秒前
852的应助被科研通管家采纳,获得10
22秒前
共享精神的应助被科研通管家采纳,获得10
22秒前
殷宵箫发布了新的文献求助10
22秒前
英姑的应助被科研通管家采纳,获得10
22秒前
含蓄的芝麻完成签到,获得积分10
24秒前
ADAB0002完成签到,获得积分10
25秒前
果冻完成签到 ,获得积分10
26秒前
26秒前
vfdhjng完成签到,获得积分20
28秒前
28秒前
可爱的函函的应助被lx采纳,获得10
30秒前
31秒前
华仔的应助被怡宝采纳,获得10
32秒前
summerer发布了新的文献求助20
33秒前
34秒前
嘻嘻哈哈的应助被Gloria采纳,获得10
34秒前
费洛蒙漩涡完成签到,获得积分10
35秒前
孤独孤风完成签到,获得积分10
35秒前
苹果颖完成签到,获得积分10
36秒前
lx完成签到,获得积分10
37秒前
38秒前
38秒前
科研通AI6.4的应助被殷宵箫采纳,获得10
38秒前
39秒前
鱼鱼鱼完成签到,获得积分10
41秒前
lx发布了新的文献求助10
43秒前
43秒前
顺心尔冬完成签到,获得积分10
43秒前
44秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8165846
求助须知:如何正确求助?哪些是违规求助? 9559318
关于积分的说明 21749858
捐赠科研通 7756681
什么是DOI,文献DOI怎么找? 3429083
关于科研通互助平台的介绍 2553354
邀请新用户注册赠送积分活动 2473622